Riskx Investments Exits Position in ABIOMED (ABMD)

ABIOMED (ABMD) : Riskx Investments has sold out all of its stake in ABIOMED during the most recent quarter, according to the disclosure filed by the company on Aug 1, 2016 with the SEC. The investment management company has sold out 8,253 shares of ABIOMED which is valued at $978,641.

Other Hedge Funds, Including , Diversified Trust Co reduced its stake in ABMD by selling 2,090 shares or 13.28% in the most recent quarter. The Hedge Fund company now holds 13,645 shares of ABMD which is valued at $1,582,411. ABIOMED makes up approx 0.22% of Diversified Trust Co’s portfolio.Capstone Asset Management Co reduced its stake in ABMD by selling 6,320 shares or 47.16% in the most recent quarter. The Hedge Fund company now holds 7,080 shares of ABMD which is valued at $831,935. ABIOMED makes up approx 0.02% of Capstone Asset Management Co’s portfolio.Gw&k Investment Management boosted its stake in ABMD in the latest quarter, The investment management firm added 3,065 additional shares and now holds a total of 31,251 shares of ABIOMED which is valued at $3,672,149. ABIOMED makes up approx 0.07% of Gw&k Investment Management’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in ABMD in the latest quarter, The investment management firm added 15,422 additional shares and now holds a total of 16,062 shares of ABIOMED which is valued at $1,833,477. ABIOMED makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.

ABIOMED opened for trading at $118.73 and hit $121.57 on the upside on Thursday, eventually ending the session at $121.41, with a gain of 2.39% or 2.83 points. The heightened volatility saw the trading volume jump to 5,49,692 shares. Company has a market cap of $5,188 M.

On the company’s financial health, ABIOMED reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.

Leave a Reply

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.